Poolbeg Pharma plc
Poolbeg Pharma plc

Poolbeg Pharma plc share price, news, views and interviews

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation. 

Poolbeg Pharma

POLB 001

POLB 001 is a Phase II-ready p38 MAP Kinase inhibitor that reduces harmful inflammation (‘cytokine storm’) in patients with severe influenza

Influenza is a serious disease that infects 12% of the global population each year, causes of 5-10 million hospitalisations and ~500,000 deaths. Many more suffer serious complications such as sudden, serious cardiac events, tissue damage, pneumonia and sepsis.

Further Assets

Poolbeg Pharma has access to a unique private repository of clinical samples and associated data from human challenge trials. This resource is anticipated to expand over coming years. Human challenge trial data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease. 

 

biotechnology
Testing

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Poolbeg Pharma plc

Poolbeg Pharma plc share price

Fundamentals

Analyst Notes & Comments

Latest Poolbeg Pharma plc News

Interviews

Questions & Answers

Broker Notes & Comments

Poolbeg Pharma plc share price

Fundamentals

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.